Stay updated on LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.

Latest updates to the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedThe page revision updates from v3.0.1 to v3.0.2, indicating a new release; the 'Back to Top' link has been removed, with no other substantive content changes detected.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check19 days agoChange DetectedThe web page has updated the facility name and location details, specifically changing from 'Gent, Belgium' to 'Ghent, Belgium'. Additionally, there are updates to the drug names listed, with 'durvalumab' being retained and 'LY3022855' and 'tremelimumab' added.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.